clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Jenkins H et al. | Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. | 2017 | Clin Drug Investig | pmid:27928738 |
Takemoto Y et al. | Disseminated Mycobacterium scrofulaceum Infection in an Immunocompetent Host. | 2017 | Intern. Med. | pmid:28717096 |
Alba C et al. | Antibiotic resistance in Helicobacter pylori. | 2017 | Curr. Opin. Infect. Dis. | pmid:28704226 |
Mishima E et al. | Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. | 2017 | Intern. Med. | pmid:28674358 |
Sun W et al. | Synergistic drug combination effectively blocks Ebola virus infection. | 2017 | Antiviral Res. | pmid:27890675 |
Shimoyama T et al. | Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. | 2017 | Intern. Med. | pmid:28674348 |
Hung IFN et al. | Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. | 2017 | Chest | pmid:27884765 |
Ustundag GH et al. | The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. | 2017 | Can J Gastroenterol Hepatol | pmid:28656129 |
Peng X et al. | Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. | 2017 | Int J Med Sci | pmid:28638276 |
Ozturk O et al. | Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. | 2017 | Arab J Gastroenterol | pmid:28601610 |
Aguilera-Correa JJ et al. | Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. | 2017 | Diagn. Microbiol. Infect. Dis. | pmid:27863951 |
Alirezaei A et al. | Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis Versus Nonuremic Patients. | 2017 | Iran J Kidney Dis | pmid:28575885 |
Cosme A et al. | Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. | 2017 | World J. Gastroenterol. | pmid:28566898 |
Angol DC et al. | from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. | 2017 | Biomed Res Int | pmid:28555193 |
Ivanová L et al. | Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. | 2017 | Environ. Res. | pmid:28183039 |
Varma MV et al. | Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. | 2017 | Clin. Pharmacol. Ther. | pmid:27648490 |
Huet D et al. | [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. | 2017 | Rev Mal Respir | pmid:27639948 |
El Haj C et al. | The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? | 2017 | Med. Microbiol. Immunol. | pmid:27639707 |
Jia L et al. | Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. | 2017 | Bioorg. Med. Chem. Lett. | pmid:28711353 |
Seyama S et al. | Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). | 2017 | J. Antimicrob. Chemother. | pmid:27999037 |
Zerbetto De Palma G et al. | Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. | 2017 | Microb. Drug Resist. | pmid:27391421 |
Legendre T et al. | [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. | 2017 | Encephale | pmid:27178256 |
Choi HS et al. | Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. | 2017 | Jpn. J. Infect. Dis. | pmid:27169951 |
Serrano CA et al. | Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. | 2017 | J. Pediatr. Gastroenterol. Nutr. | pmid:27159208 |
Abadi ATB | Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. | 2017 | World J. Gastroenterol. | pmid:29085187 |
Pastukh N et al. | GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. | 2017 | Helicobacter | pmid:29058343 |
Tognetti L et al. | Bullous impetigo during interstitial pneumonitis. | 2017 | G Ital Dermatol Venereol | pmid:29050448 |
Chen MJ et al. | Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. | 2017 | J. Antimicrob. Chemother. | pmid:28961996 |
Kim SY et al. | Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. | 2017 | Helicobacter | pmid:28940815 |
Mukherjee D et al. | Vancomycin and Clarithromycin Show Synergy against . | 2017 | Antimicrob. Agents Chemother. | pmid:28923867 |
Souto Filho JTD et al. | Long-term complete remission of primary gastric plasmacytoma following endoscopic resection. | 2017 | Ann. Hematol. | pmid:28315923 |
Antonakos N et al. | Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. | 2017 | Crit Care | pmid:28274246 |
Koratala A et al. | Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. | 2017 | Blood Purif. | pmid:28268216 |
Lin CM et al. | Is ionizing radiation a risk factor to diffuse panbronchiolitis? | 2017 | QJM | pmid:28069906 |
de Ãvila BE et al. | Micromotor-enabled active drug delivery for in vivo treatment of stomach infection. | 2017 | Nat Commun | pmid:28814725 |
Zhang D et al. | Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial. | 2017 | Medicine (Baltimore) | pmid:28796053 |
Fraser AG | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776748 |
Jung YS et al. | Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. | 2017 | Aliment. Pharmacol. Ther. | pmid:28776746 |
Makihara K et al. | Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. | 2017 | Cancer Chemother. Pharmacol. | pmid:28711984 |
Tanabe H et al. | Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. | 2017 | Dig. Dis. Sci. | pmid:28664410 |
Fohner AE et al. | PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. | 2017 | Pharmacogenet. Genomics | pmid:28146011 |
Iwayama K et al. | Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression. | 2017 | BMC Pharmacol Toxicol | pmid:28235416 |
Komiya K et al. | Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. | 2017 | Respir. Res. | pmid:28219384 |
Sakurai K et al. | Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. | 2017 | World J. Gastroenterol. | pmid:28216974 |
Awan S et al. | Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. | 2017 | Lung Cancer | pmid:28213005 |
Su J et al. | Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. | 2017 | Medicine (Baltimore) | pmid:28207505 |
Branquinho D et al. | Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? | 2017 | BMC Gastroenterol | pmid:28202013 |
Inukai K et al. | Effect of gel formation on the dissolution behavior of clarithromycin tablets. | 2017 | Int J Pharm | pmid:28196716 |
Miftahussurur M et al. | Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. | 2017 | Am. J. Trop. Med. Hyg. | pmid:28193745 |
Zhang Z et al. | In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. | 2017 | Int. J. Antimicrob. Agents | pmid:28188830 |